Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 10/20 | 0.33 |
| ▸ | CDK8 | P49336 | 10/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3119994 | 1.00 | OTUD7B (0.46) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| Hydrochloric Acid SCHEMBL2637685 | 0.97 | OTUD7B (0.44) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| Hydrochloric Acid SCHEMBL325043 | 0.97 | OTUD7B (0.44) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| Hydrochloric Acid SCHEMBL30159811 | 0.97 | OTUD7B (0.44) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| SCHEMBL21238918 | 0.91 | OTUD7B (0.41) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| SCHEMBL479513 | 0.89 | — | — | |
| SCHEMBL2023430 | 0.88 | CRBN (0.39) | OTUD7BCRBNNEK2HSD17B10 | |
| SCHEMBL23009666 | 0.86 | CRBN (0.38) | OTUD7BCRBNNEK2HSD17B10 | |
| SCHEMBL21224581 | 0.86 | CRBN (0.38) | OTUD7BCRBNNEK2HSD17B10 | |
| Hydrochloric Acid SCHEMBL2026185 | 0.86 | CRBN (0.38) | OTUD7BCRBNNEK2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104411-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-05-22 | — | — | WO | claimed |
| CN-119301132-A | Halogenated indole macrocyclic compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | claimed |
| EP-3792256-B1 | PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2024-10-23 | — | — | EP | claimed |
| WO-2024119028-A1 | SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| CN-117980297-A | Substituted aminopyridine compounds as EGFR inhibitors | 柳韩洋行 | 2024-05-03 | — | — | CN | claimed |
| CN-115151534-B | Inhibitors of interleukin-1 receptor associated kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof and methods of use thereof | 南京药石科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2023232776-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-07 | — | — | WO | claimed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | claimed |
| EP-4161921-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| CN-115916776-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2023-04-04 | — | — | CN | claimed |
| WO-2012004604-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2012-01-12 | — | — | WO | claimed |
| EP-2373652-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI (FR) | 2011-10-12 | — | — | EP | claimed |
| WO-2010065803-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | claimed |
| EP-1455792-B1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | claimed |
| US-7019001-B2 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | claimed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | claimed |
| EP-1455792-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | claimed |
| US-6727247-B2 | ADENOSINE RECEPTOR LIGANDS IN A METHOD OF TREATMENT, CONTROL, OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2004-04-27 | — | — | US | claimed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | claimed |
| WO-2003049741-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | OTUD7B 4282/4885CRBN 4707/4885NEK2 1657/4885 |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | OTUD7B 4052/4885CRBN 3174/4885NEK2 3719/4885 |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | OTUD7B 4282/4885CRBN 4707/4885NEK2 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.